Bioequivalence of oral products and the biopharmaceutics classification system: Science, regulation, and public policy

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 3, 2011, Pages 467-470

  Amidon, K S ^a   Langguth, P ^b   Lennernas H ^c   Yu, L ^d   Amidon, G L ^e  

^a IOWA STATE UNIVERSITY   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UPPSALA UNIVERSITY   (Sweden)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; GENERIC DRUG;

ARTICLE; BIOEQUIVALENCE; CLASSIFICATION; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG METABOLISM; DRUG PENETRATION; HUMAN; NONHUMAN; POLICY; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; BIOPHARMACEUTICS; DRUGS, GENERIC; HUMANS; PHARMACEUTICAL PREPARATIONS; POLICY; THERAPEUTIC EQUIVALENCY;

EID: 80052037863     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.109     Document Type: Article

References (24)

1. Benet, L.Z. & Larregieu, C.A. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin. Pharmacol. Ther. 88, 405-407 (2010).
2. US Food and Drug Administration. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf (2000).
3. Amidon, G.L., Lennernäs, H., Shah, V.P. & Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420 (1995).
4. US Food and Drug Administration. Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book) http://www.accessdata.fda.gov/scripts/ cder/ob/default.cfm pp. 1-3 (2010).
5. Chen, M.L. et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm. Res. 18, 1645-1650 (2001).
6. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on the Investigation of Bioequivalence http://www.ema.europa.eu/docs/ en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf (2010).
7. Carpenter, D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA (Princeton University Press, Princeton, NJ, 2010).
8. Drug Bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States. J. Pharmacokinet. Biopharm. 2, 433-466 (1974).
9. Castle, W.B., Astwood, E.B., Finland, M. & Keefer, C.S. White paper on the therapeutic equivalence of chemically equivalent drugs. JAMA 208, 1171-1172 (1969).
10. T obbell, D.A. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970. Bull. Hist. Med. 82, 878-912 (2008).
11. US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Oral Administered Drug Products-General Considerations (2003).
12. Yu, L.X. et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19, 921-925 (2002). (Pubitemid 34804232)
13. Wu, C.Y. & Benet, L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23 (2005). (Pubitemid 40558141)
14. Chen, M.L. & Yu, L. The use of drug metabolism for prediction of intestinal permeability (dagger). Mol. Pharm. 6, 74-81 (2009).
15. US Food and Drug Administration. Guidance for Industry: Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (1995).
16. S ousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B. & Basit, A.W. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363, 1-25 (2008).
17. Lennernäs, H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 37, 1015-1051 (2007). (Pubitemid 350035536)
18. S un, D. et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19, 1400-1416 (2002). (Pubitemid 35266543)
19. Volpe, D.A. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J. Pharm. Sci. 97, 712-725 (2008). (Pubitemid 351293876)
20. Volpe, D.A. Application of method suitability for drug permeability classification. AAPS J. 12, 670-678 (2010).
21. Yang, Y., Faustino, P.J., Volpe, D.A., Ellison, C.D., Lyon, R.C. & Yu, L.X. Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Mol. Pharm. 4, 608-614 (2007). (Pubitemid 47310172)
22. T akagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L.X. & Amidon, G.L. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol. Pharm. 3, 631-643 (2006). (Pubitemid 46087480)
23. Dahan, A. et al. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol. Pharm. (2010); e-pub ahead of print 3 September 2010.
24. Roffey, S.J., Obach, R.S., Gedge, J.I. & Smith, D.A. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 39, 17-43 (2007).